EADV Highlights

Sonja Ständer, EADV 2021: New Therapies for Chronic Pruritus and Prurigo

touchIMMUNOLOGY had the great pleasure of speaking with Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) about new treatments for chronic pruritus and prurigo. Her presentation entitled ‘New treatments for chronic pruritus and prurigo’ was given at the EADV 30th Congress, 29 Sep – 2 Oct. Disclosures: Prof. Sonja Ständer has acted as an investigator […]

Dermatological Conditions

Sonja Ständer, EADV 2021: Nemolizumab in the Treatment of Prurigo Nodularis

Prof. Sonja Ständer (University Hospital Münster, Münster, Germany) kindly took the time to speak to us about the health burden of prurigo and recent investigations into the IL-31 targeted therapy, nemolizumab. Her presentation entitled ‘Nemolizumab rapidly relieves itch and sleep disturbances in patients with prurigo nodularis’ was given at the EADV 30th Congress, 29 Sep […]

COVID-19

David Pesqué, EADV 2021: mRNA COVID-19 Vaccine Skin Reactions

It was an absolute pleasure to speak with Dr David Pesqué (Universitat Autònoma de Barcelona, Barcelona, Spain) about his study investigating the skin reactions seen in response to mRNA COVID-19 vaccines. His presentation entitled ‘Clinical characterization of skin reactions due to mRNA COVID-19 vaccines at a tertiary-level hospital: a descriptive study’ was given at the […]

Vitilgo

David Rosmarin, EADV 2021: Efficacy and Safety of Ruxolitinib Cream in Vitiligo

Dr David Rosmarin (Tufts Medical Center, Boston, MA, USA) kindly took the time to speak with touchIMMUNOLOGY about the results from the safety and efficacy studies investigating ruxolitinib cream in vitiligo. His presentation entitled ‘Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: 24-Week Results From 2 Randomized, Double-Blind Phase 3 Studies’ was […]

Alopecia Areata

Brett King, EADV 2021: JAK Inhibitors in the Treatment of Alopecia Areata

It was an absolute pleasure to be able to speak with Dr Brett King (Yale School of Medicine, New Haven, CT, USA) about the recent efficacy and safety results presented around the JAK inhibitors, baricitinib and ritlecitinib, in the treatment of alopecia areata. His presentations entitled ‘Efficacy and Safety of Ritlecitinib (PF-06651600) in Patients with […]

Psoriasis

Andy Blauvelt, EADV 2021: Deucravacitinib vs Placebo and Apremilast in Scalp Psoriasis

touchIMMUNOLOGY had the pleasure of speaking with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the oral TYK2 inhibitor, deucravacitinib, and how it compared to placebo and apremilast in the treatment of scalp psoriasis. His presentation entitled ‘Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Scalp […]

Atopic Dermatitis

Andy Blauvelt, EADV 2021: Switching from Dupilumab to Upadacitinib in Atopic Dermatitis

It was a pleasure to speak with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the results from the recent open-label study investigating the efficacy and safety of switching from dupilumab to upadacitinib in the treatment of atopic dermatitis. His presentation entitled ‘Efficacy and Safety of Switching from Dupilumab to Upadacitinib in […]

Dermatological Conditions

Esther van Zuuren, EADV 2021: Rosacea Classification

It was a pleasure to be able to catch up with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) to discuss rosacea classification and how this can impact treatment choices. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you […]

Psoriasis

Tiago Torres, EADV Spring Symposium 2021: Psoriasis Session Highlights

It was a pleasure to discuss with Prof. Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) his highlights from the psoriasis session he chaired at the EADV Spring Symposium, 6-7 May 2021. Questions Could you give us a brief overview of the presentations on the psoriasis session that you chaired at EADV? (0:18) How has […]

FILTER YOUR SEARCH

Speciality: